OUTPATIENT TREATMENT OF PATIENTS WITH CANCER AND VENOUS THROMBOEMBOLISM
DOI:
https://doi.org/10.6016/ZdravVestn.1178Keywords:
cancer, venous thromboembolism, ambulatory anticoagulant treatment, survivalAbstract
Background: Patients with cancer are at increased risk for venous thromboembolism (VTE). Cancer-associated VTE increases the burden of malignant disease and has an unfavorable effect on survival.
Aim: To establish the safety and efficiency of ambulatory treatment of patients with cancer and VTE.
Methods: In retrospective longitudinal cohort study we investigated documentation of all patients with cancer and VTE who were ambulatory treated at our department from November 2005 to February 2011. Their clinical features and complications while on anticoagulant treatment were analyzed. Patients were followed for at least two years from the date of VTE event.
Results: 290 patients with cancer and VTE were enrolled (134 women; mean age 68±12 years; 78,2% proximal venous thrombosis (VT); 10% pulmonary embolism (PE); 74,5% metastatic disease). They were treated with low-molecular-weight heparin (LMWH) in the first six months, later on with coumarins. 94 bleeding (33% major and 67% minor) and 41 recurrent VTE events (34,2% PE and 65,8% VT) were recorded. Two-year survival rate was 45,5%. The cause of death was progression of cancer in 87,4%, major bleeding in 2,5% and PE in 1,9% of patients. Advanced stage of cancer, low body mass index and low hemoglobin concentration at initiation of anticoagulant treatment turned out to be the independent prognostic factors of survival.
Conclusions: Ambulatory treatment of patients with cancer and VTE is safe and efficient. Survival of patients with cancer and VTE predominantly depends on advanced stage of cancer and general performance status of a patient.
Downloads
References
Blom JW, Doggen CJM, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005; 293(6): 715–22.
Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011; 9 suppl 1: 316–24.
Lee AY, Levine MN. Venous Thromboembolism and Cancer: Risk and Outcomes. Circulation. 2003; 107(23 Suppl 1): I17–21.
Gussoni G, Frasson S, La Regina M, Di Micco P, Monreal M. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from RIETE registry. Thromb Res. 2013; 131(1): 24–30.
Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancer associated with venous thromboembolism. N Engl J Med. 2000; 343(25): 1846–50.
Prandoni P, Lensing AW, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100(10): 3484–8.
Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007; 5(3): 632–4.
Vižintin Cuderman T, Štalc M. Venski trombembolizmi. In: Mavri A, ed. Priročnik za uporabo novih peroralnih antikoagulacijskih zdravil v klinični praksi. Ljubljana: Slovensko zdravniško društvo, Sekcija za antikoagulacijsko zdravljenje in preprečevanje trombemboličnih bolezni pri Združenju za žilne bolezni; 2012. p. 48–62.
Farge D, Debourdeau P, Beckers M, Baglin C, Bauersachs RM, Brenner B, et al. International clinical practice guidelines for the treatment and prophylaxis of veonus thromboembolism in patients with cancer. J Thromb Haemost. 2013; 11(1): 56–70.
Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, et al. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141(2 Suppl): e419S–94S.
Lyman GH, Khorana AA, Kuderer NM, Lee AY, Arcelus JI, Balaban EP, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31(17): 2189–204.
Mandala M, Falanga A, Roila F. Managment of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2011; 22 suppl 6: vi85–92.
Streiff MB. The National Comprehensive Cancer Center Network (NCCN) guidelines on the management of venous thromboembolism in cancer patients. Thromb Res. 2010; 125 suppl 2: S128–33.
O'Shaughnessy D, Miles J, Wimperis J. UK patients with deep-vein thrombosis can be safely treated as out-patients. QJM. 2000; 93(10): 663–7.
Dunn AS, Coller B. Outpatient treatment of deep vein thrombosis: translating clinical trials into practice. Am J Med. 1999; 106(6): 660–9.
Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of anticoagulant therapy. Thromb Haemost. 1993; 69(3): 263–9.
Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005; 6(6): 401–10.
Wells PS, Kovacs MJ, Bormanis J, Forgie MA, Goudie D, Morrow B, et al. Expanding eligibility for outpatient treatment of deep venous thrombosis and pulmonary embolism with low-molecular-weight-heparin: a comparison of patient self-injection with homecare injection. Arch Intern Med. 1998; 158(16): 1809–12.
Zidane M, van Hulsteijn LH, Brenninkmeijer BJ, Huisman MV. Out of hospital treatment with subcutaneous low molecular weight heparin in patients with acute deep-vein thrombosis: a prospective study in daily practice. Haematologica. 2006; 91(8): 1052–8.
Zondag W, Mos IC, Creemers-Schild D, Hoogerbrugge AD, Dekkers OM, Dolsma J, et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost. 2011; 9(8): 1500–7.
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolsim and its effect on survival among patients with common cancers. Arch Intern Med. 2006; 166(4): 458–64.
Cronin-Fenton DP, Søndergaard F, Pedersen LA, Frvzek JP, Cetin K, Acquavella J, et al. Hospitalization for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010; 103(7): 947–53.
Primic Žakelj M, Bračko M, Hočevar M, Jarm K, Pompe–Kirn V, Strojan P, et al., eds. Rak v Sloveniji 2009. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2013. Dosegljivo 15. 7. 2013 s spletne strani: http://www.onko-i.si/fileadmin/onko/datoteke/dokumenti/RRS/LP_2009.pdf
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349(2): 146–53.
Louzada ML, Majeed H, Wells PS. Efficacy of low-molecular-weight-heparin versus vitamin K anatgonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res. 2009; 123(6): 837–44.
Kahn SR, Springmann V, Schulman S, Martineau J, Stewart JA, Komari N, et al. Managment and adherence to VTE treatment guidelines in a national prospective cohort study in the Canadian outpatient setting. The Recovery Study. Thromb Haemost. 2012; 108(3): 493–8.
Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl): 401S–28S.
Trujillo-Santos J, Nieto JA, Ruiz-Gamietea A, Lopez-Jimenez L, Garcia-Bragado F, Quintavalla R, et al. Bleeding complications associated with anticoagulant therapy in patients with cancer. Thromb Res. 2010; 125 suppl 2: S58–S61.
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
